Gyre Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	11.81	33.51	25.18
Short-Term Investments	14.86	-	-
Cash & Short-Term Investments	26.67	33.51	25.18
Cash Growth	-20.41%	33.10%	-
Accounts Receivable	19.59	15.16	15.61
Other Receivables	5.19	1.29	-
Receivables	29.15	16.84	17.14
Inventory	6.34	4.28	6.12
Prepaid Expenses	1.19	1.55	0.38
Other Current Assets	1.44	1.05	0.84
Total Current Assets	64.79	57.22	49.65
Property, Plant & Equipment	25.7	23.78	18.38
Long-Term Investments	24.57	23.43	7.39
Other Intangible Assets	1.71	1.7	1.86
Long-Term Deferred Tax Assets	5.62	4.7	4.08
Other Long-Term Assets	3.03	5.72	3.39
Total Assets	125.41	116.54	84.75
Accounts Payable	0.11	0.36	0.12
Accrued Expenses	9.3	10.56	6.77
Current Portion of Leases	0.71	0.21	0.49
Current Income Taxes Payable	2.83	5.05	2.1
Current Unearned Revenue	0.16	0.08	0.17
Other Current Liabilities	6.41	3.79	2.59
Total Current Liabilities	19.52	20.05	12.24
Long-Term Leases	0.89	0.2	0.12
Long-Term Unearned Revenue	0.93	0.21	0.12
Other Long-Term Liabilities	5.68	17.61	0.06
Total Liabilities	27	38.07	12.54
Common Stock	0.09	0.08	0.06
Additional Paid-In Capital	136.19	68.18	32.8
Retained Earnings	-70.36	-82.44	10.06
Comprehensive Income & Other	-2.6	-1.64	-0.39
Total Common Equity	63.32	-15.83	42.52
Minority Interest	35.08	29.78	29.7
Shareholders' Equity	98.4	78.47	72.22
Total Liabilities & Equity	125.41	116.54	84.75
Total Debt	1.6	0.41	0.61
Net Cash (Debt)	25.07	33.1	24.56
Net Cash Growth	-24.25%	34.76%	-
Net Cash Per Share	0.25	0.50	0.32
Filing Date Shares Outstanding	93.61	85.42	63.59
Total Common Shares Outstanding	86.31	76.6	63.59
Working Capital	45.27	37.17	37.41
Book Value Per Share	0.73	-0.21	0.67
Tangible Book Value	61.61	-17.53	40.67
Tangible Book Value Per Share	0.71	-0.23	0.64
Buildings	18.98	12.29	10.84
Machinery	10.28	7.39	5.69
Construction In Progress	0.22	7.88	4.85
Leasehold Improvements	-	-	0.33

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q